ARC Medical Devices
ARC is a clinical stage company developing the only liquid medical device that forms a barrier film to prevent surgical adhesions throughout the entire abdominopelvic cavity. Our nonclinical data show superior efficacy compared with three of the top marketed products. We are currently completing a volume escalation, safety clinical trial. Proceeds from our Series B financing will be used to start and complete a US Phase 2 efficacy and safety clinical trial in 100 patients undergoing pelvic/gynecological surgery; prosecute and maintain 8 new patent families and 3 previously issued patent families; and to support manufacturing and market access/reimbursement activities.
Presenter: Chris Springate, CEO
Read More
MY01
MY01 Inc. is on a mission to empower healthcare professionals with the ability to pre-empt severe medical conditions thereby improving patient outcomes. We are commercial and saving limbs with our MY01 Continuous Intracompartment Pressure Monitor.
Presenter: Charles Allan, CEO
Read More
Nanovista Inc.
Nanovista is developing novel imaging agents for surgical oncology with the lead product, CF800, enabling cancer surgeons to visualize tumors in real time during surgery. Even the most skilled surgeons capture as little as 30-60% of the tumor margins in challenging disease areas. Nanovista's CF800 liposomal imaging agent accumulates specifically at tumor margins and is ideally suited to visualize all solid tumors. CF800 works with existing operating room near-infrared imaging equipment and illuminates tumors both at the surgery planning phase and inside the operating room, with the potential to significantly improve cancer surgery outcomes. The company is raising capital for Phase I development of CF800 in lung cancer and head and neck cancer.
Presenter: Anton Neschadim, Chief Executive
Read More
Synergy Disc Replacement
SDRi is a Canadian spinal medical device company pioneering a revolutionary artificial disc replacement implant technology - the only artificial disc implant that can both preserve motion and restore alignment to the spine. With a CE mark, Synergy has begun early commercialization efforts in last couple years in Europe and Australia. We have completed more than 1000 implants of the Synergy Disc with no device related adverse events. Synergy is now raising $15M USD to complete its FDA IDE clinical trial in pursuit of USA market approval, the largest market in the world for cervical artificial disc implants.
Presenter: Josh Butters, CEO
Read More
